RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company’s discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune…
Browsing: Ideas & Technologies
Multikine® Therapy Treats Newly Diagnosed Head and Neck Cancer Patients Before They Undergo Surgery, Radiation, or Chemotherapy CEL-SCI Corporation is a publicly-traded (NYSE: CVM) Phase III cancer immunotherapy company with operations in the Baltimore area. CEL-SCI develops immunotherapy products for the treatment of cancer and infectious diseases, based on the…
Aphios Pharma is Now Developing Cannabis-Based Treatment for Opioid Addition Aphios Corporation is a Woburn, MA-based, clinical-stage biotechnology company that is developing green enabling technology platforms to improve drug discovery, manufacturing, nanotechnology drug delivery, and pathogenic safety. Aphios is delivering enhanced therapeutic products to improve quality-of-life and treat chronic diseases…
Therapy Targets AFP Receptors Found in Over 80 Percent of Cancer Cells Alpha Cancer Technologies Inc. (ACT) is a Toronto-based clinical-stage biotechnology company that is developing drugs for oncology and auto-immune disease indications. Alpha Cancer Technologies’ products include Alpha-Fetoprotein (AFP), a human protein produced by the embryo during fetal development;…
RNA Disruption Assay™ Test Can Determine Degree of Ribosomal RNA Disruption During Chemotherapy Rna Diagnostics Inc. is a Toronto-based early-stage molecular diagnostics company that is developing medical diagnostic tools to assist in the management of cancer. The company’s first product, RNA Disruption Assay™ (RDA™), is a novel test that helps…
“20/20 Hindsight” Platform Improves Accuracy of Most Widely Used Cancer Biomarkers 20/20 GeneSystems, Inc. is a Rockville, MD-based, digital diagnostics company focused on reducing cancer mortality through early detection. 20/20 GeneSystems is pioneering a novel approach to cancer detection, called “20/20 Hindsight”, that uses continuous machine learning to utilize large…
Q1© Platform Takes Unique Approach to Isolation and Interrogation of Individual Cancer Cells QuantumCyte is a Silicon Valley-based early-stage biotechnology company that is developing a unique drug assay system. QuantumCyte’s single-cell analysis system, known as Q1©, can predict drug efficacy in a way that is rapid, non-invasive, and accurate. Q1©…
CAR T Cell Therapy May Change Cancer Patients’ Own Weak T Cells into “Bionic Killing Machines” Aurora Biopharma is a Cambridge, MA-based, clinical-stage company that is developing state-of-the-art cancer immunotherapy, utilizing a form of adoptive cell transfer called Chimeric Antigen Receptor (CAR) T Cell Therapy. The therapy genetically edits patients’…